Novartis announces the company’s financial results for the second quarter and first half of 2025.Novartis announces the company’s financial results for the second quarter and first half of 2025.
Showing 97 results
-
Lutathera®
( lutetium Lu 177 dotatate )Neuroendocrine TumorsAvailable in -
Lucentis®
( ranibizumab )Ophthalmology -
Locametz®
( gallium Ga 68 gozetotide ) -
Lescol® XL
( fluvastatin sodium )Cardiovascular, Renal and Metabolism -
Lescol®
( fluvastatin sodium )Cardiovascular, Renal and Metabolism -
Leqvio®
( inclisiran )Innovative Medicines -
Kymriah®
( tisagenlecleucel-T )Oncology -
Kisqali® Femara® Co-Pack
-
Kisqali®
( ribociclib )Oncology